Journal
ARCHIVES OF MICROBIOLOGY
Volume 191, Issue 8, Pages 631-638Publisher
SPRINGER
DOI: 10.1007/s00203-009-0490-y
Keywords
Klebsiella pneumoniae; ESBL; Tellurium compound; Antimicrobial agents
Categories
Funding
- Dr. Tovi Comet-Walerstein Cancer Research Chair
- The Dave and Florence Muskovitz Chair in Cancer Research
- The Frieda Stollman Cancer Memorial Fund
- Rappaport Foundation for Microbiology, Bar-Ilan University, Israel
Ask authors/readers for more resources
Due to the extensive spread of antibiotic-resistant Klebsiella pneumoniae, the non-toxic immunomodulator, ammonium trichloro (dioxoethylene-o, o') tellurate (AS101), was introduced for the first time in this study. Eleven strains of K. pneumoniae were tested: five were extended spectrum beta lactamase (ESBL)-producing strains and six were non-ESBL-producing strains. The MIC and MBC of ten strains were 9 mu g/ml AS101 and 18 mu g/ml for one strain. AS101 treatment inhibited bacterial growth in a dose-dependent manner on protein-rich media. No inhibition by AS101 was observed on poorer media. In combination with beta-mercaptoethanol (2-ME) or cysteamine, AS101 inhibited bacterial growth in both types of media. Growth inhibition was also shown following AS101 treatment at both lag and log phases. Our data indicate that AS101 enters the bacterium through its porins, causing bacterial destruction. The mechanism of cell death was characterized using several techniques: (a) scanning electron microscopy showed that bacteria treated with AS101 or in combination with cysteamine exhibited evidence of cell-wall damage; (b) X-ray microanalysis demonstrated damage to Na/K pumps; and (c) transmission electron microscopy demonstrated cell lysis. These phenomena suggest that AS101 has antibacterial potential against K. pneumoniae infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available